Palmitoylethanolamide - Prismic Pharmaceuticals

Drug Profile

Palmitoylethanolamide - Prismic Pharmaceuticals

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Epitech Group
  • Developer Prismic Pharmaceuticals
  • Class Anti-inflammatories; Cannabinoids; Ethanolamines; Neuroprotectants; Palmitic acids
  • Mechanism of Action Cannabinoid receptor agonists; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Inflammation
  • No development reported Pain

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for clinical-Phase-Unknown development in Pain(Combination therapy) in USA
  • 11 Feb 2015 palmitoylethanolamide - Prismic Pharmaceuticals is available for licensing in World as of 13 Aug 2013.
  • 03 Feb 2015 Clinical trials in Pain (Combination therapy) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top